molmed

Investors

The European Commission grants a Conditional Marketing Authorisation to Zalmoxis®

The European Commission grants a Conditional Marketing Authorisation to Zalmoxis® ▾

Investors

The Board of Directors approves the first half-year financial report ended June 30, 2016

The Board of Directors approves the first half-year financial report ended June 30, 2016 ▾

Investors

MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis(R)

MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis(R) ▾

Investors

Half-year financial report as of 30 June 2016

Half-year financial report as of 30 June 2016 ▾

Investors

MolMed receives positive CHMP opinion recommending conditional marketing authorisation for Zalmoxis(R)

MolMed receives positive CHMP opinion recommending conditional marketing authorisation for Zalmoxis(R) ▾

Investors

MolMed and Oxford BioMedica reviewed and expanded the existing license agreements’ framework

MolMed and Oxford BioMedica reviewed and expanded the existing license agreements’ framework ▾

Investors

MolMed Board of Directors approved the interim financial report ended March 31, 2016 Pdf

MolMed Board of Directors approved the interim financial report ended March 31, 2016 Pdf ▾

Investors

Variation in the financial calendar for year 2016

Variation in the financial calendar for year 2016 ▾

Investors

Outcome of shareholders' meeting and board of directors

Outcome of shareholders' meeting and board of directors ▾

Investors

Ordinary shareholders' meeting April 18 2016

Ordinary shareholders' meeting April 18 2016 ▾

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.